Cargando…

Colorectal Cancer Survivors Suffering From Sensory Chemotherapy-Induced Peripheral Neuropathy Are Not a Homogenous Group: Secondary Analysis of Patients’ Profiles With Oxaliplatin-Induced Peripheral Neuropathy

Oxaliplatin, a pivotal drug in the management of colorectal cancer, causes chemotherapy-induced peripheral neuropathy (CIPN) in a third of cancer survivors. Based on a previous cross-sectional study assessing oxaliplatin-related sensory CIPN in colorectal cancer survivors, a secondary analysis was d...

Descripción completa

Detalles Bibliográficos
Autores principales: Kerckhove, Nicolas, Selvy, Marie, Lambert, Céline, Gonneau, Coralie, Feydel, Gabrielle, Pétorin, Caroline, Vimal-Baguet, Agnès, Melnikov, Sergey, Kullab, Sharif, Hebbar, Mohamed, Bouché, Olivier, Slimano, Florian, Bourgeois, Vincent, Lebrun-Ly, Valérie, Thuillier, Frédéric, Mazard, Thibault, Tavan, David, Benmammar, Kheir Eddine, Monange, Brigitte, Ramdani, Mohamed, Péré-Vergé, Denis, Huet-Penz, Floriane, Bedjaoui, Ahmed, Genty, Florent, Leyronnas, Cécile, Busserolles, Jérôme, Trévis, Sophie, Pinon, Vincent, Pezet, Denis, Balayssac, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8599933/
https://www.ncbi.nlm.nih.gov/pubmed/34803689
http://dx.doi.org/10.3389/fphar.2021.744085
_version_ 1784601043625050112
author Kerckhove, Nicolas
Selvy, Marie
Lambert, Céline
Gonneau, Coralie
Feydel, Gabrielle
Pétorin, Caroline
Vimal-Baguet, Agnès
Melnikov, Sergey
Kullab, Sharif
Hebbar, Mohamed
Bouché, Olivier
Slimano, Florian
Bourgeois, Vincent
Lebrun-Ly, Valérie
Thuillier, Frédéric
Mazard, Thibault
Tavan, David
Benmammar, Kheir Eddine
Monange, Brigitte
Ramdani, Mohamed
Péré-Vergé, Denis
Huet-Penz, Floriane
Bedjaoui, Ahmed
Genty, Florent
Leyronnas, Cécile
Busserolles, Jérôme
Trévis, Sophie
Pinon, Vincent
Pezet, Denis
Balayssac, David
author_facet Kerckhove, Nicolas
Selvy, Marie
Lambert, Céline
Gonneau, Coralie
Feydel, Gabrielle
Pétorin, Caroline
Vimal-Baguet, Agnès
Melnikov, Sergey
Kullab, Sharif
Hebbar, Mohamed
Bouché, Olivier
Slimano, Florian
Bourgeois, Vincent
Lebrun-Ly, Valérie
Thuillier, Frédéric
Mazard, Thibault
Tavan, David
Benmammar, Kheir Eddine
Monange, Brigitte
Ramdani, Mohamed
Péré-Vergé, Denis
Huet-Penz, Floriane
Bedjaoui, Ahmed
Genty, Florent
Leyronnas, Cécile
Busserolles, Jérôme
Trévis, Sophie
Pinon, Vincent
Pezet, Denis
Balayssac, David
author_sort Kerckhove, Nicolas
collection PubMed
description Oxaliplatin, a pivotal drug in the management of colorectal cancer, causes chemotherapy-induced peripheral neuropathy (CIPN) in a third of cancer survivors. Based on a previous cross-sectional study assessing oxaliplatin-related sensory CIPN in colorectal cancer survivors, a secondary analysis was designed to explore the possibility that different clusters of patients may co-exist among a cohort of patients with oxaliplatin-related CIPN. Other objectives were to characterize these clusters considering CIPN severity, anxiety, depression, health-related quality of life (HRQOL), patients’ characteristics and oxaliplatin treatments. Among the 96 patients analyzed, three clusters were identified (cluster 1: 52, cluster 2: 34, and cluster 3: 10 patients). Clusters were significantly different according to CIPN severity and the proportion of neuropathic pain (cluster 1: low, cluster 2: intermediate, and cluster 3: high). Anxiety, depressive disorders and HRQOL alteration were lower in cluster 1 in comparison to clusters 2 and 3, but not different between clusters 2 and 3. This study underlines that patients with CIPN are not a homogenous group, and that CIPN severity is associated with psychological distress and a decline of HRQOL. Further studies are needed to explore the relation between clusters and CIPN management.
format Online
Article
Text
id pubmed-8599933
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-85999332021-11-19 Colorectal Cancer Survivors Suffering From Sensory Chemotherapy-Induced Peripheral Neuropathy Are Not a Homogenous Group: Secondary Analysis of Patients’ Profiles With Oxaliplatin-Induced Peripheral Neuropathy Kerckhove, Nicolas Selvy, Marie Lambert, Céline Gonneau, Coralie Feydel, Gabrielle Pétorin, Caroline Vimal-Baguet, Agnès Melnikov, Sergey Kullab, Sharif Hebbar, Mohamed Bouché, Olivier Slimano, Florian Bourgeois, Vincent Lebrun-Ly, Valérie Thuillier, Frédéric Mazard, Thibault Tavan, David Benmammar, Kheir Eddine Monange, Brigitte Ramdani, Mohamed Péré-Vergé, Denis Huet-Penz, Floriane Bedjaoui, Ahmed Genty, Florent Leyronnas, Cécile Busserolles, Jérôme Trévis, Sophie Pinon, Vincent Pezet, Denis Balayssac, David Front Pharmacol Pharmacology Oxaliplatin, a pivotal drug in the management of colorectal cancer, causes chemotherapy-induced peripheral neuropathy (CIPN) in a third of cancer survivors. Based on a previous cross-sectional study assessing oxaliplatin-related sensory CIPN in colorectal cancer survivors, a secondary analysis was designed to explore the possibility that different clusters of patients may co-exist among a cohort of patients with oxaliplatin-related CIPN. Other objectives were to characterize these clusters considering CIPN severity, anxiety, depression, health-related quality of life (HRQOL), patients’ characteristics and oxaliplatin treatments. Among the 96 patients analyzed, three clusters were identified (cluster 1: 52, cluster 2: 34, and cluster 3: 10 patients). Clusters were significantly different according to CIPN severity and the proportion of neuropathic pain (cluster 1: low, cluster 2: intermediate, and cluster 3: high). Anxiety, depressive disorders and HRQOL alteration were lower in cluster 1 in comparison to clusters 2 and 3, but not different between clusters 2 and 3. This study underlines that patients with CIPN are not a homogenous group, and that CIPN severity is associated with psychological distress and a decline of HRQOL. Further studies are needed to explore the relation between clusters and CIPN management. Frontiers Media S.A. 2021-11-04 /pmc/articles/PMC8599933/ /pubmed/34803689 http://dx.doi.org/10.3389/fphar.2021.744085 Text en Copyright © 2021 Kerckhove, Selvy, Lambert, Gonneau, Feydel, Pétorin, Vimal-Baguet, Melnikov, Kullab, Hebbar, Bouché, Slimano, Bourgeois, Lebrun-Ly, Thuillier, Mazard, Tavan, Benmammar, Monange, Ramdani, Péré-Vergé, Huet-Penz, Bedjaoui, Genty, Leyronnas, Busserolles, Trévis, Pinon, Pezet and Balayssac. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Kerckhove, Nicolas
Selvy, Marie
Lambert, Céline
Gonneau, Coralie
Feydel, Gabrielle
Pétorin, Caroline
Vimal-Baguet, Agnès
Melnikov, Sergey
Kullab, Sharif
Hebbar, Mohamed
Bouché, Olivier
Slimano, Florian
Bourgeois, Vincent
Lebrun-Ly, Valérie
Thuillier, Frédéric
Mazard, Thibault
Tavan, David
Benmammar, Kheir Eddine
Monange, Brigitte
Ramdani, Mohamed
Péré-Vergé, Denis
Huet-Penz, Floriane
Bedjaoui, Ahmed
Genty, Florent
Leyronnas, Cécile
Busserolles, Jérôme
Trévis, Sophie
Pinon, Vincent
Pezet, Denis
Balayssac, David
Colorectal Cancer Survivors Suffering From Sensory Chemotherapy-Induced Peripheral Neuropathy Are Not a Homogenous Group: Secondary Analysis of Patients’ Profiles With Oxaliplatin-Induced Peripheral Neuropathy
title Colorectal Cancer Survivors Suffering From Sensory Chemotherapy-Induced Peripheral Neuropathy Are Not a Homogenous Group: Secondary Analysis of Patients’ Profiles With Oxaliplatin-Induced Peripheral Neuropathy
title_full Colorectal Cancer Survivors Suffering From Sensory Chemotherapy-Induced Peripheral Neuropathy Are Not a Homogenous Group: Secondary Analysis of Patients’ Profiles With Oxaliplatin-Induced Peripheral Neuropathy
title_fullStr Colorectal Cancer Survivors Suffering From Sensory Chemotherapy-Induced Peripheral Neuropathy Are Not a Homogenous Group: Secondary Analysis of Patients’ Profiles With Oxaliplatin-Induced Peripheral Neuropathy
title_full_unstemmed Colorectal Cancer Survivors Suffering From Sensory Chemotherapy-Induced Peripheral Neuropathy Are Not a Homogenous Group: Secondary Analysis of Patients’ Profiles With Oxaliplatin-Induced Peripheral Neuropathy
title_short Colorectal Cancer Survivors Suffering From Sensory Chemotherapy-Induced Peripheral Neuropathy Are Not a Homogenous Group: Secondary Analysis of Patients’ Profiles With Oxaliplatin-Induced Peripheral Neuropathy
title_sort colorectal cancer survivors suffering from sensory chemotherapy-induced peripheral neuropathy are not a homogenous group: secondary analysis of patients’ profiles with oxaliplatin-induced peripheral neuropathy
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8599933/
https://www.ncbi.nlm.nih.gov/pubmed/34803689
http://dx.doi.org/10.3389/fphar.2021.744085
work_keys_str_mv AT kerckhovenicolas colorectalcancersurvivorssufferingfromsensorychemotherapyinducedperipheralneuropathyarenotahomogenousgroupsecondaryanalysisofpatientsprofileswithoxaliplatininducedperipheralneuropathy
AT selvymarie colorectalcancersurvivorssufferingfromsensorychemotherapyinducedperipheralneuropathyarenotahomogenousgroupsecondaryanalysisofpatientsprofileswithoxaliplatininducedperipheralneuropathy
AT lambertceline colorectalcancersurvivorssufferingfromsensorychemotherapyinducedperipheralneuropathyarenotahomogenousgroupsecondaryanalysisofpatientsprofileswithoxaliplatininducedperipheralneuropathy
AT gonneaucoralie colorectalcancersurvivorssufferingfromsensorychemotherapyinducedperipheralneuropathyarenotahomogenousgroupsecondaryanalysisofpatientsprofileswithoxaliplatininducedperipheralneuropathy
AT feydelgabrielle colorectalcancersurvivorssufferingfromsensorychemotherapyinducedperipheralneuropathyarenotahomogenousgroupsecondaryanalysisofpatientsprofileswithoxaliplatininducedperipheralneuropathy
AT petorincaroline colorectalcancersurvivorssufferingfromsensorychemotherapyinducedperipheralneuropathyarenotahomogenousgroupsecondaryanalysisofpatientsprofileswithoxaliplatininducedperipheralneuropathy
AT vimalbaguetagnes colorectalcancersurvivorssufferingfromsensorychemotherapyinducedperipheralneuropathyarenotahomogenousgroupsecondaryanalysisofpatientsprofileswithoxaliplatininducedperipheralneuropathy
AT melnikovsergey colorectalcancersurvivorssufferingfromsensorychemotherapyinducedperipheralneuropathyarenotahomogenousgroupsecondaryanalysisofpatientsprofileswithoxaliplatininducedperipheralneuropathy
AT kullabsharif colorectalcancersurvivorssufferingfromsensorychemotherapyinducedperipheralneuropathyarenotahomogenousgroupsecondaryanalysisofpatientsprofileswithoxaliplatininducedperipheralneuropathy
AT hebbarmohamed colorectalcancersurvivorssufferingfromsensorychemotherapyinducedperipheralneuropathyarenotahomogenousgroupsecondaryanalysisofpatientsprofileswithoxaliplatininducedperipheralneuropathy
AT boucheolivier colorectalcancersurvivorssufferingfromsensorychemotherapyinducedperipheralneuropathyarenotahomogenousgroupsecondaryanalysisofpatientsprofileswithoxaliplatininducedperipheralneuropathy
AT slimanoflorian colorectalcancersurvivorssufferingfromsensorychemotherapyinducedperipheralneuropathyarenotahomogenousgroupsecondaryanalysisofpatientsprofileswithoxaliplatininducedperipheralneuropathy
AT bourgeoisvincent colorectalcancersurvivorssufferingfromsensorychemotherapyinducedperipheralneuropathyarenotahomogenousgroupsecondaryanalysisofpatientsprofileswithoxaliplatininducedperipheralneuropathy
AT lebrunlyvalerie colorectalcancersurvivorssufferingfromsensorychemotherapyinducedperipheralneuropathyarenotahomogenousgroupsecondaryanalysisofpatientsprofileswithoxaliplatininducedperipheralneuropathy
AT thuillierfrederic colorectalcancersurvivorssufferingfromsensorychemotherapyinducedperipheralneuropathyarenotahomogenousgroupsecondaryanalysisofpatientsprofileswithoxaliplatininducedperipheralneuropathy
AT mazardthibault colorectalcancersurvivorssufferingfromsensorychemotherapyinducedperipheralneuropathyarenotahomogenousgroupsecondaryanalysisofpatientsprofileswithoxaliplatininducedperipheralneuropathy
AT tavandavid colorectalcancersurvivorssufferingfromsensorychemotherapyinducedperipheralneuropathyarenotahomogenousgroupsecondaryanalysisofpatientsprofileswithoxaliplatininducedperipheralneuropathy
AT benmammarkheireddine colorectalcancersurvivorssufferingfromsensorychemotherapyinducedperipheralneuropathyarenotahomogenousgroupsecondaryanalysisofpatientsprofileswithoxaliplatininducedperipheralneuropathy
AT monangebrigitte colorectalcancersurvivorssufferingfromsensorychemotherapyinducedperipheralneuropathyarenotahomogenousgroupsecondaryanalysisofpatientsprofileswithoxaliplatininducedperipheralneuropathy
AT ramdanimohamed colorectalcancersurvivorssufferingfromsensorychemotherapyinducedperipheralneuropathyarenotahomogenousgroupsecondaryanalysisofpatientsprofileswithoxaliplatininducedperipheralneuropathy
AT perevergedenis colorectalcancersurvivorssufferingfromsensorychemotherapyinducedperipheralneuropathyarenotahomogenousgroupsecondaryanalysisofpatientsprofileswithoxaliplatininducedperipheralneuropathy
AT huetpenzfloriane colorectalcancersurvivorssufferingfromsensorychemotherapyinducedperipheralneuropathyarenotahomogenousgroupsecondaryanalysisofpatientsprofileswithoxaliplatininducedperipheralneuropathy
AT bedjaouiahmed colorectalcancersurvivorssufferingfromsensorychemotherapyinducedperipheralneuropathyarenotahomogenousgroupsecondaryanalysisofpatientsprofileswithoxaliplatininducedperipheralneuropathy
AT gentyflorent colorectalcancersurvivorssufferingfromsensorychemotherapyinducedperipheralneuropathyarenotahomogenousgroupsecondaryanalysisofpatientsprofileswithoxaliplatininducedperipheralneuropathy
AT leyronnascecile colorectalcancersurvivorssufferingfromsensorychemotherapyinducedperipheralneuropathyarenotahomogenousgroupsecondaryanalysisofpatientsprofileswithoxaliplatininducedperipheralneuropathy
AT busserollesjerome colorectalcancersurvivorssufferingfromsensorychemotherapyinducedperipheralneuropathyarenotahomogenousgroupsecondaryanalysisofpatientsprofileswithoxaliplatininducedperipheralneuropathy
AT trevissophie colorectalcancersurvivorssufferingfromsensorychemotherapyinducedperipheralneuropathyarenotahomogenousgroupsecondaryanalysisofpatientsprofileswithoxaliplatininducedperipheralneuropathy
AT pinonvincent colorectalcancersurvivorssufferingfromsensorychemotherapyinducedperipheralneuropathyarenotahomogenousgroupsecondaryanalysisofpatientsprofileswithoxaliplatininducedperipheralneuropathy
AT pezetdenis colorectalcancersurvivorssufferingfromsensorychemotherapyinducedperipheralneuropathyarenotahomogenousgroupsecondaryanalysisofpatientsprofileswithoxaliplatininducedperipheralneuropathy
AT balayssacdavid colorectalcancersurvivorssufferingfromsensorychemotherapyinducedperipheralneuropathyarenotahomogenousgroupsecondaryanalysisofpatientsprofileswithoxaliplatininducedperipheralneuropathy